title: Cancer metabolism: new validated targets for drug discovery.
abstract: Recent studies in cancer metabolism directly implicate catabolic fibroblasts as a new rich source of i) energy and ii) biomass, for the growth and survival of anabolic cancer cells. Conversely, anabolic cancer cells upregulate oxidative mitochondrial metabolism, to take advantage of the abundant fibroblast fuel supply. This simple model of "metabolic-symbiosis" has now been independently validated in several different types of human cancers, including breast, ovarian, and prostate tumors. Biomarkers of metabolic-symbiosis are excellent predictors of tumor recurrence, metastasis, and drug resistance, as well as poor patient survival. New pre-clinical models of metabolic-symbiosis have been generated and they genetically validate that catabolic fibroblasts promote tumor growth and metastasis. Over 30 different stable lines of catabolic fibroblasts and >10 different lines of anabolic cancer cells have been created and are well-characterized. For example, catabolic fibroblasts harboring ATG16L1 increase tumor cell metastasis by >11.5-fold, despite the fact that genetically identical cancer cells were used. Taken together, these studies provide >40 novel validated targets, for new drug discovery and anti-cancer therapy. Since anabolic cancer cells amplify their capacity for oxidative mitochondrial metabolism, we should consider therapeutically targeting mitochondrial biogenesis and OXPHOS in epithelial cancer cells. As metabolic-symbiosis promotes drug-resistance and may represent the escape mechanism during anti-angiogenic therapy, new drugs targeting metabolic-symbiosis may also be effective in cancer patients with recurrent and advanced metastatic disease.
authors.affiliation: Manchester Breast Centre and Breakthrough Breast Cancer Research Unit, Faculty Institute of Cancer Sciences, University of Manchester, UK.
authors.forename: Federica
authors.initials: F
authors.lastname: Sotgia
authors.forename: Ubaldo E
authors.initials: UE
authors.lastname: Martinez-Outschoorn
authors.forename: Michael P
authors.initials: MP
authors.lastname: Lisanti
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D055808:Drug Discovery; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents
references.citation: Cell Cycle. 2011 Aug 1;10(15):2440-9
references.pmid: 21734470
references.citation: Cell Cycle. 2013 Sep 1;12(17):2723-32
references.pmid: 23860382
references.citation: Cell Cycle. 2011 Dec 1;10(23):4047-64
references.pmid: 22134189
references.citation: Cancer Biol Ther. 2011 Dec 15;12(12):1101-13
references.pmid: 22236875
references.citation: Cell Cycle. 2012 Jul 1;11(13):2545-56
references.pmid: 22722266
references.citation: Cell Cycle. 2011 Jun 15;10(12):2021-34
references.pmid: 21646868
references.citation: Cell Cycle. 2011 Aug 1;10(15):2521-8
references.pmid: 21768775
references.citation: Cell Cycle. 2012 Nov 15;11(22):4174-80
references.pmid: 23070475
references.citation: Cell Cycle. 2010 Jun 1;9(11):2201-19
references.pmid: 20519932
references.citation: Am J Pathol. 2011 May;178(5):1949-52
references.pmid: 21514412
references.citation: Cell Cycle. 2012 Sep 15;11(18):3403-14
references.pmid: 22918248
references.citation: Cell Cycle. 2010 Jun 15;9(12):2423-33
references.pmid: 20562526
references.citation: Mol Cancer Res. 2013 Jun;11(6):579-92
references.pmid: 23475953
references.citation: Antioxid Redox Signal. 2012 Jun 1;16(11):1264-84
references.pmid: 21883043
references.citation: Cell Cycle. 2011 Aug 1;10(15):2504-20
references.pmid: 21778829
references.citation: Cell Cycle. 2010 Aug 15;9(16):3256-76
references.pmid: 20814239
references.citation: Cell Cycle. 2012 Jun 15;11(12):2272-84
references.pmid: 22684333
references.citation: Cell Cycle. 2012 Apr 1;11(7):1445-54
references.pmid: 22395432
references.citation: Cell Cycle. 2013 Jun 1;12(11):1791-801
references.pmid: 23656776
references.citation: Cell Cycle. 2011 Apr 15;10(8):1271-86
references.pmid: 21512313
references.citation: Cell Cycle. 2012 Nov 1;11(21):3964-71
references.pmid: 23082722
references.citation: Nat Med. 2011 Oct 30;17(11):1498-503
references.pmid: 22037646
references.citation: Cell Cycle. 2010 Sep 1;9(17):3485-505
references.pmid: 20861672
references.citation: Cell Cycle. 2012 Dec 1;11(23):4390-401
references.pmid: 23172368
references.citation: Clin Cancer Res. 2013 Feb 1;19(3):571-85
references.pmid: 23236214
references.citation: Cell Cycle. 2012 Oct 1;11(19):3599-610
references.pmid: 22935696
references.citation: Cancer Cell. 2012 Mar 20;21(3):309-22
references.pmid: 22439926
references.citation: Cell Cycle. 2012 Aug 15;11(16):3019-35
references.pmid: 22874531
references.citation: Cell Cycle. 2010 Jun 15;9(12):2412-22
references.pmid: 20562527
references.citation: Cell Cycle. 2011 Jun 1;10(11):1784-93
references.pmid: 21566463
references.citation: Oncotarget. 2012 Aug;3(8):798-810
references.pmid: 22878233
references.citation: BMC Med. 2011 May 23;9:62
references.pmid: 21605374
references.citation: Cell Cycle. 2013 Aug 15;12(16):2580-97
references.pmid: 23860378
references.citation: Cell Cycle. 2012 Jun 15;11(12):2285-302
references.pmid: 22684298
references.citation: Am J Pathol. 2012 Jul;181(1):278-93
references.pmid: 22698676
references.citation: Cancer Res. 2012 Oct 1;72(19):5130-40
references.pmid: 22850421
references.citation: Cell Cycle. 2011 Dec 15;10(24):4208-16
references.pmid: 22033146
references.citation: Cell Cycle. 2011 Dec 1;10(23):4065-73
references.pmid: 22129993
references.citation: Cell Cycle. 2012 Dec 1;11(23):4402-13
references.pmid: 23172369
references.citation: Cell Cycle. 2009 Dec;8(23):3984-4001
references.pmid: 19923890
references.citation: Cell Cycle. 2011 Jul 1;10(13):2059-63
references.pmid: 21654190
references.citation: Aging (Albany NY). 2010 Apr;2(4):185-99
references.pmid: 20442453
references.citation: Cancer Biol Ther. 2009 Jun;8(11):1071-9
references.pmid: 19502809
references.citation: Cell Cycle. 2010 Sep 1;9(17):3534-51
references.pmid: 20864819
references.citation: Int J Biochem Cell Biol. 2011 Jul;43(7):1045-51
references.pmid: 21300172
references.citation: Annu Rev Pathol. 2012;7:423-67
references.pmid: 22077552
references.citation: Cell Cycle. 2013 Jan 1;12(1):172-82
references.pmid: 23257779
references.citation: Cell Cycle. 2010 Sep 1;9(17):3515-33
references.pmid: 20855962
references.citation: Cell Cycle. 2010 Nov 1;9(21):4297-306
references.pmid: 21051947
references.citation: Cancer Biol Ther. 2011 Nov 15;12(10):924-38
references.pmid: 22041887
references.citation: Cancer Biol Ther. 2011 Feb 15;11(4):383-94
references.pmid: 21150282
references.citation: Cancer Biol Ther. 2010 Sep 15;10(6):537-42
references.pmid: 20861671
references.citation: Cell Cycle. 2012 Nov 15;11(22):4152-66
references.pmid: 23047606
references.citation: Cell Cycle. 2012 Nov 1;11(21):3956-63
references.pmid: 23082721
references.citation: Cell Cycle. 2013 May 1;12(9):1360-70
references.pmid: 23574724
references.citation: Breast Cancer Res. 2011 Jul 08;13(4):213
references.pmid: 21867571
references.citation: Breast Cancer Res. 2012 Dec 07;14(6):R155
references.pmid: 23216814
references.citation: Cell Metab. 2012 Jan 4;15(1):4-5
references.pmid: 22225869
references.citation: Cell Cycle. 2013 May 1;12(9):1371-84
references.pmid: 23574725
references.citation: Cell Cycle. 2011 Jun 1;10(11):1772-83
references.pmid: 21558814
references.citation: Cell Cycle. 2012 Sep 1;11(17):3280-9
references.pmid: 22894905